Investigating Interleukin-37 As A Treatment And Biomarker For Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$677,857.00
Summary
Alzheimer’s disease (AD) is the defining healthcare condition of our generation. Finding asymptomatic at risk individuals at preclinical stages will allow initiation of therapies that will either slow or, preferably, stop the progression of the disease. Herein, we will study a protein called interleukin-37 as an early biomarker and treatment for AD.
REVERSIBLE AND IRREVERSIBLE TNF-MEDIATED COGNITIVE DECLINE
Funder
National Health and Medical Research Council
Funding Amount
$444,460.00
Summary
This proposal seeks to clarify the neuronal mechanisms underlying the inflammatory processing leading to cognitive decline. Furthermore, the research project identifies anti-inflammatory treatment options aiming at improved cognitive performance in people at risk for or suffering from cognitive impairment of neuropsychiatric disorders such as dementia and depression.
Interleukin-6 -gp130 Signaling And Actions In The CNS
Funder
National Health and Medical Research Council
Funding Amount
$549,092.00
Summary
Interleukin-6 (IL-6) is a member of a family of cytokine proteins that may be causative factors in many neurological disorders where they are involved in diverse processes including inflammation, neuronal injury and repair. In this project we will study how IL-6 affects the brain to bring about these outcomes. The results of this work will advance our understanding of how members of this cytokine family function and how they contribute to neurological disease.
Developing Novel Selective Glycine Receptor Potentiators As A Means To Control Pain.
Funder
National Health and Medical Research Council
Funding Amount
$552,647.00
Summary
It has been estimated that >3M Australians suffer from pain at a cost to the economy of >$34B, with chronic pain (persisting beyond 1-6 mths) accounting for ~half this burden. There is an urgent and compelling social and economic case for the development of safer and more effective pain therapeutics. This project takes inspiration from a new class of Australian marine natural products that selectively regulate a key pain pathway, and will optimize and develop these as a new class of pain d ....It has been estimated that >3M Australians suffer from pain at a cost to the economy of >$34B, with chronic pain (persisting beyond 1-6 mths) accounting for ~half this burden. There is an urgent and compelling social and economic case for the development of safer and more effective pain therapeutics. This project takes inspiration from a new class of Australian marine natural products that selectively regulate a key pain pathway, and will optimize and develop these as a new class of pain drug.Read moreRead less